References

Unresolved reference

External reference

Poverty, Migration, and Chagas Disease

10.1007/s40475-020-00225-y · 2021 · External reference

Global, Regional, and National Trends of Chagas Disease from 1990 to 2019: Comprehensive Analysis of the Global Burden of Disease Study

10.5334/gh.1150 · 2022 · External reference

Chagas Disease: From Discovery to a Worldwide Health Problem

10.3389/fpubh.2019.00166 · 2019 · External reference

Chagas disease in Latin America: an epidemiological update based on 2010 estimates = Maladie de Chagas en Amérique latine: le point épidémiologique basé sur les estimations de 2010

2015 · External reference

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis

10.1371/journal.pntd.0010386 · 2022 · External reference

Clinical and epidemiological aspects of Chagas disease

10.1016/s1473-3099(01)00065-2 · 2001 · External reference

Chagas disease

10.1016/s0140-6736(17)31612-4 · 2018 · External reference

Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation

10.1128/aac.05135-11 · 2012 · External reference

Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial

10.7326/0003-4819-144-10-200605160-00006 · 2006 · External reference

Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study

10.1016/j.eclinm.2020.100694 · 2020 · External reference

Unresolved reference

External reference

Adverse events associated with benznidazole treatment for Chagas disease in children and adults

10.1111/bcp.16214 · 2024 · External reference

Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease

10.1093/jac/dkx180 · 2017 · External reference

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières

2009 · External reference

Drug discovery for chagas disease: A viewpoint

10.1016/j.actatropica.2019.105107 · 2019 · External reference

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas

10.1590/0037-8682-0477-2019 · 2020 · External reference

A New Epoch in Antitrypanosomal Treatment for Chagas Disease

10.1016/j.jacc.2016.12.016 · 2017 · External reference

Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)

10.1016/b978-0-12-385863-4.00004-6 · 2011 · External reference

Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi

10.1128/aac.01742-09 · 2010 · External reference

Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial

10.1016/j.jacc.2016.12.023 · 2017 · External reference

Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease

10.1056/nejmoa1313122 · 2014 · External reference

Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial

10.1016/s1473-3099(17)30538-8 · 2018 · External reference

Efficacy of Oral Administration of E1224 in Combination with Benznidazole on Experimental Trypanosoma cruzi Infection

2015 · External reference

Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments

2013 · External reference

Multiple-dose kinetics of the trypanosomicide benznidazole in man

1980 · External reference

Single-dose pharmacokinetics of the trypanosomicide benznidazole in man

1979 · External reference

Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results

1980 · External reference

Population pharmacokinetics of benznidazole in adult patients with Chagas disease

10.1128/aac.05018-14 · 2015 · External reference

Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults

10.1371/journal.pntd.0002907 · 2014 · External reference

Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation

10.1371/journal.pntd.0010850 · 2023 · External reference

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

10.1016/s1473-3099(20)30844-6 · 2021 · External reference

Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia

10.1093/trstmh/trs004 · 2013 · External reference

Longitudinal study and specific chemotherapy in children with chronic Chagas’ disease, residing in a low endemicity area of Argentina

2004 · External reference

Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial

10.1016/s1473-3099(23)00629-1 · 2024 · External reference

Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease

10.1016/j.trstmh.2012.07.010 · 2012 · External reference

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial

10.1186/s13063-020-4226-2 · 2020 · External reference

New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients

10.1128/aac.00745-15 · 2015 · External reference

New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: Clinical, parasitological, and serological assessment after three years of follow-up

10.1128/aac.00439-20 · 2020 · External reference

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice

10.1093/infdis/jit420 · 2014 · External reference

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease

10.1126/scitranslmed.abb7656 · 2020 · External reference

Benznidazole therapy for Chagas disease in asymptomatic Trypanosoma cruzi -seropositive former blood donors: evaluation of the efficacy of different treatment regimens

10.1590/0037-8682-0165-2016 · 2016 · External reference

Review of pharmacological options for the treatment of Chagas disease

10.1111/bcp.14700 · 2022 · External reference

Translational challenges of animal models in Chagas disease drug development: a review

10.2147/dddt.s90208 · 2015 · External reference

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials

2024 · External reference

Analytical performance of a multiplex Real-Time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples

10.1371/journal.pntd.0002000 · 2013 · External reference

Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment

10.1128/aac.00845-18 · 2018 · External reference

Systematic review and meta-analysis of the pharmacokinetics of benznidazole in the treatment of Chagas disease

10.1128/aac.01567-16 · 2016 · External reference

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming

10.1016/j.cmpb.2003.11.003 · 2004 · External reference

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM

10.1016/j.cmpb.2010.04.018 · 2011 · External reference

10.32614/rj-2017-066

10.32614/rj-2017-066 · External reference

Disentangling effects of induced plant defenses and food quantity on herbivores by fitting nonlinear models

10.1086/286067 · 1997 · External reference

Unresolved reference

External reference

Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study

10.1038/sj.ki.5002374 · 2007 · External reference

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia

10.1007/s13318-017-0410-5 · 2017 · External reference

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

10.1007/s10928-007-9066-0 · 2007 · External reference

Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials

10.1128/aac.01912-16 · 2017 · External reference

New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia

10.1136/bmjopen-2021-052897 · 2021 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers

10.1128/aac.02150-19 · 2021 · External reference

Unresolved reference

1982 · External reference

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole

10.1590/0074-02760150401 · 2016 · External reference

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

10.1590/0074-0276140156 · 2014 · External reference

The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications

10.1016/j.meegid.2011.12.009 · 2012 · External reference

Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

10.1038/srep04703 · 2014 · External reference

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure

2018 · External reference

In Vivo Analysis of Trypanosoma cruzi Persistence Foci at Single-Cell Resolution

2020 · External reference

Trypanosoma cruzi amastigotes that persist in the colon during chronic stage murine infections have a reduced replication rate

10.1098/rsob.200261 · 2020 · External reference

Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice

10.1371/journal.ppat.1011627 · 2023 · External reference

Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease

10.1128/aac.00689-15 · 2015 · External reference

Benznidazole treatment: time- and dose-dependence varies with the Trypanosoma cruzi strain

2021 · External reference

Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study

10.1016/j.bcp.2018.01.005 · 2018 · External reference

Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas’ disease drug discovery

10.1371/journal.pntd.0008487 · 2020 · External reference

Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease

10.1371/journal.pntd.0012968 · 2025 · External reference